In acute myeloid leukemia (AML), activation of the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathway can result from mutated upstream targets such as class III RTKs. Here, MAP2K7 is linked to acute myeloid leukemia.